Recursion Pharmaceuticals Newsroom

KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12

Moomoo NewsOct 2 18:32 ET

Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $10

Moomoo NewsSep 5 07:35 ET

Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $11

Moomoo NewsSep 5 07:35 ET

A Quick Look at Today's Ratings for Recursion Pharmaceuticals(RXRX.US), With a Forecast Between $8 to $14

Moomoo NewsSep 4 09:00 ET

Recursion Pharmaceuticals Maintains Buy Rating Amidst Modest Study Results and Strong Financial Position

TipRanksSep 4 06:17 ET

Hold Rating on Recursion Pharmaceuticals Amidst Lukewarm Phase 2 Results and AI Platform Validation Concerns

TipRanksSep 4 05:44 ET

Recursion Pharmaceuticals Analyst Ratings

BenzingaSep 4 00:59 ET

Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $10

Moomoo NewsSep 3 08:33 ET

Recursion Pharmaceuticals (RXRX) Gets a Hold From Morgan Stanley

TipRanksSep 3 07:50 ET

Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)

TipRanksAug 13 12:38 ET

Strategic Merger and Financial Prospects Affirm Buy Rating for Recursion Pharmaceuticals

TipRanksAug 9 09:08 ET

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16

BenzingaAug 9 07:58 ET

Recursion Pharmaceuticals Analyst Ratings

BenzingaAug 9 07:57 ET

Recursion Pharmaceuticals (RXRX) Receives a Hold From TD Cowen

TipRanksAug 8 17:29 ET

Recursion Pharmaceuticals Analyst Ratings

BenzingaJul 11 07:03 ET

Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price Target

MT NewswiresJul 9 07:42 ET

Recursion Pharmaceuticals Analyst Ratings

BenzingaJun 25 07:45 ET

Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)

TipRanksMay 14 07:41 ET

Recursion Pharmaceuticals: A Buy Rating With Growth and Innovation on the Horizon

TipRanksMay 10 05:36 ET

Recursion Pharmaceuticals Analyst Ratings

BenzingaMay 10 05:33 ET